Enlivex Therapeutics Total Debt vs. Shares Owned By Institutions

ENLV Stock  USD 0.93  0.09  10.71%   
Based on Enlivex Therapeutics' profitability indicators, Enlivex Therapeutics may not be well positioned to generate adequate gross income at the present time. It has a very high chance of underperforming in December. Profitability indicators assess Enlivex Therapeutics' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 39.01 in 2024. EV To Sales is likely to drop to 37.08 in 2024. At this time, Enlivex Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 4.5 M in 2024, despite the fact that Income Before Tax is likely to grow to (27.6 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.70.79
Fairly Down
Slightly volatile
For Enlivex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enlivex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enlivex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enlivex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enlivex Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Return On Assets
(0.27)
Return On Equity
(0.61)
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Enlivex Therapeutics Shares Owned By Institutions vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Enlivex Therapeutics's current stock value. Our valuation model uses many indicators to compare Enlivex Therapeutics value to that of its competitors to determine the firm's financial worth.
Enlivex Therapeutics is rated as one of the top companies in total debt category among its peers. It also is one of the top stocks in shares owned by institutions category among its peers . The ratio of Total Debt to Shares Owned By Institutions for Enlivex Therapeutics is about  54,894 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Enlivex Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Enlivex Total Debt vs. Competition

Enlivex Therapeutics is rated as one of the top companies in total debt category among its peers. Total debt of Information Technology industry is currently estimated at about 383.1 Million. Enlivex Therapeutics adds roughly 1.03 Million in total debt claiming only tiny portion of equities under Information Technology industry.
Total debt  Workforce  Valuation  Revenue  Capitalization

Enlivex Shares Owned By Institutions vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Enlivex Therapeutics

Total Debt

 = 

Bonds

+

Notes

 = 
1.03 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Enlivex Therapeutics

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
18.80 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Enlivex Shares Owned By Institutions Comparison

Enlivex Therapeutics is currently under evaluation in shares owned by institutions category among its peers.

Enlivex Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Enlivex Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enlivex Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Enlivex Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Enlivex Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.3 M1.3 M
Income Tax Expense4.2 M4.5 M
Operating Income-29.4 M-27.9 M
Income Before Tax-29.1 M-27.6 M
Total Other Income Expense Net327 K343.4 K
Net Loss-29.1 M-27.6 M
Net Interest Income1.6 M1.6 M
Interest Income1.6 M1.6 M
Net Loss-27.2 M-25.8 M
Net Loss-28 M-26.6 M
Change To Netincome6.4 M6.7 M
Net Loss(1.56)(1.64)
Income Quality 0.81  0.68 
Net Income Per E B T 1.23  0.83 

Enlivex Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Enlivex Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enlivex Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enlivex Therapeutics' important profitability drivers and their relationship over time.

Use Enlivex Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Enlivex Therapeutics Pair Trading

Enlivex Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Enlivex Therapeutics position

In addition to having Enlivex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Thematic Idea Now

Obamacare
Obamacare Theme
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.